BMSD : 10.65048
BMSD : 10.65048
https://doi.org/10.65048/ijbmr
Search
About Us
Authors
Reviewers
Editorial Board
Contact Us

International Journal of Biological and Medical Research (IJBMR)

Original Article
Year : 2026  |  Volume : 17  |  Issue : 4  |  Page : 8765-8771 Full Version
Design and in-vitro characterization of buccal films for anti-parkinson’s drug
Int J Biol Med Res. 2026; 17(4): 8765-8771  |  DOI: 10.65048/ijbmr.2026.17.4.8765.1086
Faizan Syed Nizamuddin Syed*, Dr. Nishan N. Bobade, Dr. Vikrant P. Wankhade, Dr Sandeep C. Atram, Dr. Shrikant D. Pande, Nakul S. Dhore, Shraddha P. Malpani, Ashwin A. Pahurkar
Department of Pharmaceutics, Vidyabharati College of Pharmacy, Amravati, India
Correspondence Address :
Syed Faizan Syed Nizamuddin,
Department of Pharmaceutics,
Vidyabharati College of Pharmacy Amravati,
Sgbau University, Amravati, India
Orcid: https://orcid.org/0009-0006-8339-1896 E-mail: syed22996@gmail.com
Received: April 14, 2026 Accepted: August 2, 2026 Published: October 3, 2026

Abstract
Parkinson's disease is a neurodegenerative disorder with various motor and non-motor symptoms, causing impaired quality of life for patients. Dysphagia, one of the significant problems, results in poor patient compliance in the administration of conventional dosage forms. The buccal delivery system bypasses gastrointestinal restriction and first-pass metabolism and improves drug absorption. The present work involved the formulation of mucoadhesive buccal films of Ropinirole hydrochloride using a mixture of HPMC E15 and sodium alginate along with propylene glycol as a plasticizer using the solvent casting method. The formulations were evaluated for physicochemical properties, mechanical strength, drug-excipient compatibility, drug content, swelling and mucoadhesion, and in vitro drug release and permeation. FTIR and DSC were carried out to check drug-excipient interactions. Both of the studies showed there were no significant interactions between the drug and the excipients and were found to be compatible. All formulations were found to be of good uniformity in weight and thickness, had good folding endurance, and had a suitable surface pH. Drug content also was good and consistent in all the batches; mucoadhesive strength and residence time indicated that the formulation adheres to buccal mucosa effectively. Among all formulations, F4 exhibited the best characteristics. The F4 formulation showed maximum drug release (96.28%) in 6 hours with a better mucoadhesion profile than others. Stability studies also indicated good physical and chemical stability.
Keywords
Parkinson’s disease, Buccal films, Mucoadhesive drug delivery, In vitro drug release, Dysphagia, Bioavailability enhancement

References

[1]    Nakmode DD, Day CM, Song Y, Garg S. The Management of Parkinson's Disease: An Overview of the Current Advancements in Drug Delivery Systems. Pharmaceutics. 2023;15(5):1503. https://doi.org/10.3390/pharmaceutics15051503
[2]    Peng S, Liu P, Wang X, Li K. Global, regional and national burden of Parkinson's disease in people over 55 years of age: a systematic analysis of the global burden of disease study, 1991-2021. BMC Neurol. 2025;25(1):178. https://doi.org/10.1186/s12883-025-04191-8
[3]    Güne? M, Karavana SY. Non-Oral Drug Delivery in Parkinson's Disease: Current Applications and Future. Turk J Pharm Sci. 2022;19(3):343-352. https://doi.org/10.4274/tjps.galenos.2021.95226
[4]    Auffret M, Meuric V, Boyer E, Bonnaure-Mallet M, Vérin M. Oral Health Disorders in Parkinson's Disease: More than Meets the Eye. J Parkinsons Dis. 2021;11(4):1507-1535. https://doi.org/10.3233/JPD-212605
[5]    Leta V, Klingelhoefer L, Longardner K, Campagnolo M, Levent HÇ, Aureli F, et al. Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease. Eur J Neurol. 2023;30(5):1465-1480. https://doi.org/10.1111/ene.15734
[6]    Pamlényi K, Regdon G Jr, Jójárt-Laczkovich O, Nemes D, Bácskay I, Kristó K. Formulation and characterization of pramipexole containing buccal films for using in Parkinson's disease. Eur J Pharm Sci. 2023;187:106491. https://doi.org/10.1016/j.ejps.2023.106491
[7]    Cheng I, Sasegbon A, Hamdy S. Dysphagia treatments in Parkinson's disease: A systematic review and meta-analysis. NeurogastroenterolMotil. 2023;35(8):e14517. https://doi.org/10.1111/nmo.14517
[8]    Labeit B, Berkovich E, Claus I, Roderigo M, Schwake AL, Izgelov D, et al. Dysphagia for medication in Parkinson's disease. NPJ Parkinsons Dis. 2022;8(1):156. https://doi.org/10.1038/s41531-022-00421-9
[9]    Di Prima G, Campisi G, De Caro V. Amorphous Ropinirole-Loaded Mucoadhesive Buccal Film: A Potential Patient-Friendly Tool to Improve Drug Pharmacokinetic Profile and Effectiveness. J Pers Med. 2020;10(4):242. https://doi.org/10.3390/jpm10040242
[10]    Lai KL, Fang Y, Han H, Li Q, Zhang S, Li HY,  et al. Orally-dissolving film for sublingual and buccal delivery of ropinirole. Colloids Surf B Biointerfaces. 2018;163:9-18. https://doi.org/10.1016/j.colsurfb.2017.12.015
[11]    Shipp L, Liu F, Kerai-Varsani L, Okwuosa TC. Buccal films: A review of therapeutic opportunities, formulations & relevant evaluation approaches. J Control Release. 2022;352:1071-1092. https://doi.org/10.1016/j.jconrel.2022.10.058
[12]    Eleftheriadis GK, Ritzoulis C, Bouropoulos N, Tzetzis D, Andreadis DA, Boetker J, et al. Unidirectional drug release from 3D printed mucoadhesive buccal films using FDM technology: In vitro and ex vivo evaluation. Eur J Pharm Biopharm. 2019;144:180-192. https://doi.org/10.1016/j.ejpb.2019.09.018
[13]    Lodhi M, Dubey A, Narayan R, Prabhu P, Priya S. Formulation and evaluation of buccal film of Ivabradine hydrochloride for the treatment of stable angina pectoris. Int J Pharm Investig. 2013;3(1):47-53. https://doi.org/10.4103/2230-973X.108963
[14]    Yelave, A., & Bhagwat, G. Mucoadhesive buccal films: A novel approach for the delivery of anti-hypertensive drugs. Asian Journal of Pharmaceutical and Clinical Research. 2021;14(4):12–21. https://doi.org/10.22159/ajpcr.2021.v14i4.40654
[15]    Abd Elrady AN, Elkhatib MM, Mohamed MI, Fatouh AM. Spanlastics-Loaded Buccal Films for Improved Olmesartan Delivery and Sustained Hypertension Management: Formulation, Statistical Optimization, In Vitro and In Vivo Evaluation. J Pharm Innov 21, 156 (2026). https://doi.org/10.1007/s12247-025-10347-3
[16]    Nizamuddin SFS. Orodispersible and mucoadhesive buccal films: Advances, formulation challenges, and future perspectives in oromucosal drug delivery. Yemen Journal of Medicine, 2025;4(2), 294–302.  https://doi.org/10.63475/yjm.v4i2.0201
[17]    Nair AB, Al-Dhubiab BE, Shah J, Vimal P, Attimarad M, Harsha S. Development and evaluation of palonosetron loaded mucoadhesive buccal films. Journal of Drug Delivery Science and Technology. 2018 Oct 1;47:351-8. https://doi.org/10.1016/j.jddst.2018.08.014
[18]    Patel H, Lalan MS. Optimization of nanostructured lipid carrier (NLC)-based hybrid buccal film of quercetin (QCT) using a Quality by Design (QbD) approach for potential chemoprevention of oral cancer. International Journal of Applied Pharmaceutics, 2026;18(1), 242–249. https://doi.org/10.22159/ijap.2026v18i1.56754
[19]    Kazemi Z, Taghizadeh SM, Keshavarz ST, Lahootifard F. Effect of composition on mechanical and physicochemical properties of mucoadhesive buccal films containing buprenorphine hydrochloride: From design of experiments to optimal formulation. Journal of Drug Delivery Science and Technology. 2020;56:101578. https://doi.org/10.1016/j.jddst.2020.101578
[20]    Mady OY, Abulmeaty MMA, Donia AA, Al-Khureif AA, Al-Shoubki AA, Abudawood M, et al. Formulation and Bioavailability of Novel Mucoadhesive Buccal Films for Candesartan Cilexetil in Rats. Membranes. 2021; 11(9):659. https://doi.org/10.3390/membranes11090659
[21]    Ammanage A, Kempwade A, Rodriques P, Hiremath R. Formulation and evaluation of buccal films of piroxicam co-crystals. Future Journal of Pharmaceutical Sciences, 2020;6(16), 1–11. https://doi.org/10.1186/s43094-020-00033-1
[22]    Salawi A, Tabassum N, Zaman M, Khan MA, Siddique W, Alshamrani M, et al. Design and Evaluation of Instant Release Buccal Films of Empagliflozin: A Statistical Approach. ACS Omega. 2025;10(22):23492-23503. https://doi.org/10.1021/acsomega.5c02082
[23]    Meher JG, Tarai M, Yadav NP, Patnaik A, Mishra P, Yadav KS. Development and characterization of cellulose-polymethacrylate mucoadhesive film for buccal delivery of carvedilol. CarbohydrPolym. 2013;96(1):172-80. https://doi.org/10.1016/j.carbpol.2013.03.076
[24]    Pamlényi K, Rayya H, Hassan AAA, Jójárt-Laczkovich O, Sovány T, Pintye-Hódi K, et al. Development and Optimization of Chitosan-Ascorbate-Based Mucoadhesive Films for Buccal Delivery of Captopril. Pharmaceutics. 2025; 17(4):401. https://doi.org/10.3390/pharmaceutics17040401
[25]    De Caro V, Angellotti G, D’Agostino F, Di Prima G. Buccal Thin Films as Potent Permeation Enhancers for CytisineTransbuccal Delivery. Membranes. 2022; 12(11):1169. https://doi.org/10.3390/membranes12111169
[26]    Nair AB, Al-Dhubiab BE, Shah J, Jacob S, Saraiya V, Attimarad M, et al. Mucoadhesive buccal film of almotriptan improved therapeutic delivery in rabbit model. Saudi Pharm J. 2020;28(2):201-209. https://doi.org/10.1016/j.jsps.2019.11.022
[27]    Perioli L, Ambrogi V, Angelici F, Ricci M, Giovagnoli S, Capuccella M, Rossi C. Development of mucoadhesive patches for buccal administration of ibuprofen. J Control Release. 2004 Sep 14;99(1):73-82. https://doi.org/10.1016/j.jconrel.2004.06.005


 


IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications